Evidence map›Paper›PMID 42434142›Full record

ReviewFrontiers in cardiovascular medicine2026

Lactylation: a metabolic-epigenetic driver in atherosclerosis pathogenesis and therapeutic targeting.

Wenbo Lv, Linxi Xie, Jintao Tao, Qingqi Xu, Wenfeng Hu, Hao Xie, Pin Lu, Ying Xu, Liang Huang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenbo Lv *Research Laboratory of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Linxi Xie *Research Laboratory of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Jintao TaoResearch Laboratory of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Qingqi XuResearch Laboratory of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Wenfeng HuResearch Laboratory of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Hao XieResearch Laboratory of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Pin LuResearch Laboratory of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Ying XuResearch Laboratory of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Liang HuangResearch Laboratory of Translational Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis (AS), a disease of large and medium-sized arteries, is a common cause of cardiovascular morbidity and mortality. Lactylation is a recently identified post-translational modification involving the addition of lactate-derived lactyl groups to lysine residues on proteins. Studies suggest that lactylation plays a vital role in AS development by regulating several key pathological processes. These include inflammation, epithelial-mesenchymal transition, angiogenesis, vascular smooth muscle cell senescence and transdifferentiation, and metabolic dysregulation associated with atherosclerosis. This review summarizes the molecular mechanisms through which lactylation contributes to AS initiation and progression, providing a clearer understanding of the underlying pathophysiological processes. Further elucidation of lactylation may provide novel mechanistic insights into AS development and identify lactylation-targeted interventions as promising strategies to slow AS progression and reduce cardiovascular events.

Indexed as

atherosclerosisepigenetic regulationlactate metabolismlactylationvascular inflammation

Identifiers

PMID42434142
PMCPMC13349905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.